市場調査レポート

商品コード

インフルエンザの世界市場

The Global Influenza Market

出版日: 2025年05月06日
発行: BCC Research
ページ情報: 英文 188 Pages
納期: 即納可能

価格

PDF & Excel (Single User License)

USD 4,650 680,388円

レポートPDFおよびExcelを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は、機能制限があるわけではありませんが、1回までとされます。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (2-5 Users)

USD 5,580 816,465円

レポートPDFおよびExcelを同一国内の5名迄にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は計5回までとされます。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,696 979,758円

レポートPDFおよびExcelを同一事業所に所属される方にて人数に制限なく共有ご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。印刷機能に回数制限はありませんが、印刷したもののご利用はPDFのご利用者と同一範囲内です。

PDF & Excel (Enterprise License)

USD 8,035 1,175,681円

レポートPDFおよびExcelを同一企業の全ての事業所（資本100%子会社含む）にて人数に制限なく共有ご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。印刷機能に回数制限はなく、同一企業内にて配布ご利用可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.32円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界のインフルエンザの市場規模は、2024年の90億ドルから、2029年末には128億ドルに達すると予測されており、2024年から2029年の予測期間におけるCAGRは7.2％です。

北米市場は、2024年の45億ドルから、2029年には63億ドルに拡大すると見込まれており、同期間のCAGRは7.3％です。欧州市場は、2024年に24億ドルとされ、2029年には33億ドルに達すると予測されており、CAGRは6.8％です。

当レポートでは、世界のインフルエンザの市場を調査し、市場概要、市場影響因子および市場機会の分析、法規制環境、新興技術および技術開発の動向、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

市場力学
重要ポイント
市場促進要因
迅速検査と分子技術の開発
新しい治療法と診断に対する政府の支援と資金提供
インフルエンザワクチンに関する国民の意識の高まり
市場抑制要因
限られたサプライヤーが支配する治療薬市場
インフルエンザワクチンの保管と供給にかかる高コスト
市場機会
インフルエンザワクチンの強力なパイプライン
予防、治療、ワクチンへのアクセスの改善を求める声

第4章規制状況

概要
インフルエンザワクチンに関する規制
米国インフルエンザシーズンにおける三価ワクチン
EMAにより承認されたインフルエンザワクチン
インフルエンザ治療薬に関する規制状況
インフルエンザ検出キットの承認プロセス
感度
特異性

第5章新たな動向とパイプライン分析

概要
インフルエンザ診断の進歩
SHINE技術
電気化学バイオセンサー
ウェアラブルラボオンチップデバイス
量子ドットと蛍光ナノ粒子
インフルエンザ診断におけるAIの役割
インフルエンザワクチンにおける新技術
ユニバーサルインフルエンザワクチン
mRNAベースのインフルエンザワクチン
ナノテクノロジーベースのワクチン
パッチ型ワクチン
インフルエンザ治療の進歩
ナノ粒子ベースの治療法
臨床試験における潜在的な薬剤
特許分析
重要ポイント

第6章市場セグメンテーション分析

セグメンテーションの内訳
世界のインフルエンザ市場：製品区分別
インフルエンザ診断
インフルエンザワクチン
インフルエンザ治療薬
地理的内訳
重要ポイント
北米
欧州
アジア太平洋
その他

第7章競合情報

インフルエンザワクチン市場の企業シェア分析
インフルエンザ診断市場における企業シェア分析
インフルエンザ治療薬市場における企業シェア分析
ベンチャー資金調達と投資の情勢
市場における主な発展

第8章インフルエンザ市場における持続可能性：ESGの観点

概要
ESGリスク評価
総論

第9章付録

調査手法
出典
略語
企業プロファイル
ABBOTT
ASTRAZENECA
BD
BIOCRYST PHARMACEUTICALS INC.
CSL
DAIICHI SANKYO CO. LTD.
DANAHER CORP.
F. HOFFMANN-LA ROCHE LTD.
GSK PLC.
HOLOGIC INC.
QUIDELORTHO CORP.
SANOFI
SEKISUI DIAGNOSTICS
THERMO FISHER SCIENTIFIC INC.
VIATRIS INC.
新興スタートアップ企業/市場ディスラプター

図表

List of Tables

Summary Table : Global Influenza Market, by Region, Through 2029
Table 1 : History of Influenza Pandemics, 1729-2021
Table 2 : Confirmed Cases of Influenza, 2022-2024
Table 3 : Influenza Vaccines in Clinical Trials, 2024
Table 4 : Vaccines Licensed for Use in the U.S., 2024
Table 5 : FDA-Approved Influenza Drugs, 1966-2018
Table 6 : Approved Influenza Drugs in Other Countries
Table 7 : FDA-Approved Influenza Detection Tests, 2024
Table 8 : List of Vaccine Pipelines for Influenza Virus-based Platform, 2024
Table 9 : List of Vaccine Pipelines for Non-VLP Nanoparticles Platform, 2024
Table 10 : List of Vaccine Pipelines for Nucleic Acid-based Platform, 2024
Table 11 : List of Vaccine Pipelines for Recombinant Proteins Platform, 2024
Table 12 : List of Vaccine Pipelines for Virus-like particles (VLP) Platform, 2024
Table 13 : List of Vaccine Pipelines for Virus-vectored Platform, 2024
Table 14 : Influenza Drugs in Clinical Trials, 2024
Table 15 : List of Several Granted Patents in Influenza Vaccine, 2023-2025
Table 16 : List of Several Granted Patents in Influenza Diagnosis Tools, 2023-2025
Table 17 : List of Several Granted Patents in Influenza Drugs, 2023-2025
Table 18 : Global Influenza Market, by Product Segment, Through 2029
Table 19 : Global Influenza Diagnostics Market, by Type, Through 2029
Table 20 : Influenza Virus Testing Methods, 2024
Table 21 : FDA-Approved Influenza Detection Devices, 2022-2025
Table 22 : Global Influenza Diagnostics Market, by Region, Through 2029
Table 23 : Influenza Vaccine Products for the 2024-2025 Influenza Season
Table 24 : Global Influenza Vaccines Market, by Type, Through 2029
Table 25 : Seasonal Influenza Vaccines Pricing, 2024-2025
Table 26 : Global Influenza Vaccines Market, by Region, Through 2029
Table 27 : Global Influenza Therapeutics Market, by Region, Through 2029
Table 28 : Global Influenza Market, by Region, Through 2029
Table 29 : North American Influenza Market, by Product Segment, Through 2029
Table 30 : North American Influenza Market, by Country, Through 2029
Table 31 : Results of Tests Performed by Clinical Laboratories in the U.S., 2020-2024
Table 32 : Results of Tests Performed by Clinical Laboratories in the U.S., 2024-2025 Season
Table 33 : The U.S. Influenza Market, by Product Segment, Through 2029
Table 34 : Number of Influenza Detection in Canada, by Age Group, 2024-2025 Season
Table 35 : Canadian Influenza Market, by Product Segment, Through 2029
Table 36 : Influenza Vaccination Coverage in Mexico, 2018-2023
Table 37 : Mexican Influenza Market, by Product Segment, Through 2029
Table 38 : European Influenza Market, by Product Segment, Through 2029
Table 39 : European Influenza Market, by Country, Through 2029
Table 40 : Influenza Vaccination Coverage in Germany, 2018-2023
Table 41 : German Influenza Market, by Product Segment, Through 2029
Table 42 : Vaccines Marketed in U.K. for 2024-2025 Influenza Season
Table 43 : Influenza Vaccination Coverage in U.K., 2018-2023
Table 44 : U.K. Influenza Market, by Product Segment, Through 2029
Table 45 : Influenza Vaccination Coverage in France, 2018-2023
Table 46 : French Influenza Market, by Product Segment, Through 2029
Table 47 : Influenza Vaccines for Use in Pediatrics in Spain, 2024-2025 Season
Table 48 : Spanish Influenza Market, by Product Segment, Through 2029
Table 49 : Italian Influenza Market, by Product Segment, Through 2029
Table 50 : Rest of European Influenza Market, by Product Segment, Through 2029
Table 51 : Asia-Pacific Influenza Market, by Product Segment, Through 2029
Table 52 : Asia-Pacific Influenza Market, by Country, Through 2029
Table 53 : Chinese Influenza Market, by Product Segment, Through 2029
Table 54 : Japanese Influenza Market, by Product Segment, Through 2029
Table 55 : Indian Influenza Market, by Product Segment, Through 2029
Table 56 : Australian Influenza Market, by Product Segment, Through 2029
Table 57 : Rest of Asia-Pacific Influenza Market, by Product Segment, Through 2029
Table 58 : Rest of World Influenza Market, by Product Segment, Through 2029
Table 59 : Rest of World Influenza Market, by Country, Through 2029
Table 60 : South American Influenza Market, by Product Segment, Through 2029
Table 61 : Middle Eastern and African Influenza Market, by Product Segment, Through 2029
Table 62 : Recent Venture Fundings in the Influenza Market, 2024
Table 63 : Recent Key Developments in Influenza Market, 2023 and 2024
Table 64 : ESG Risk Rankings for Influenza Market Companies, 2025*
Table 65 : Report Information Sources
Table 66 : Abbreviations Used in the Global Influenza Market
Table 67 : Abbott: Company Snapshot
Table 68 : Abbott: Financial Performance, FY 2022 and 2023
Table 69 : Abbott: Product Portfolio
Table 70 : Abbott: News/Key Developments, 2024
Table 71 : AstraZeneca: Company Snapshot
Table 72 : AstraZeneca: Financial Performance, FY 2022 and 2023
Table 73 : AstraZeneca: Product Portfolio
Table 74 : AstraZeneca: News/Recent Developments, 2023 and 2024
Table 75 : BD: Company Snapshot
Table 76 : BD: Financial Performance, FY 2022 and 2023
Table 77 : BD: Product Portfolio
Table 78 : BD: News/Key Developments, 2021-2023
Table 79 : BioCryst Pharmaceuticals Inc.: Company Snapshot
Table 80 : BioCryst Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 81 : BioCryst Pharmaceuticals Inc.: Product Portfolio
Table 82 : CSL: Company Snapshot
Table 83 : CSL: Financial Performance, FY 2022 and 2023
Table 84 : CSL: Product Portfolio
Table 85 : CSL: News/Key Developments, 2022-2024
Table 86 : Daiichi Sankyo Co. Ltd.: Company Snapshot
Table 87 : Daiichi Sankyo Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 88 : Daiichi Sankyo Co. Ltd.: Product Portfolio
Table 89 : Daiichi Sankyo Co. Ltd.: News/Key Developments, 2023
Table 90 : Danaher Corp.: Company Snapshot
Table 91 : Danaher Corp.: Financial Performance, FY 2022 and 2023
Table 92 : Danaher Corp.: Product Portfolio
Table 93 : Danaher Corp: News/Recent Developments, 2021 and 2022
Table 94 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 95 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 96 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 97 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2024
Table 98 : GSK Plc.: Company Snapshot
Table 99 : GSK Plc.: Financial Performance, FY 2022 and 2023
Table 100 : GSK Plc.: Product Portfolio
Table 101 : GSK Plc.: News/Key Developments, 2024
Table 102 : Hologic Inc.: Company Snapshot
Table 103 : Hologic Inc.: Financial Performance, FY 2022 and 2023
Table 104 : Hologic Inc.: Product Portfolio
Table 105 : Hologic Inc.: News/Key Developments, 2022
Table 106 : QuidelOrtho Corp.: Company Snapshot
Table 107 : QuidelOrtho Corp.: Financial Performance, FY 2022 and 2023
Table 108 : QuidelOrtho Corp.: Product Portfolio
Table 109 : QuidelOrtho Corp.: News/Key Developments, 2024
Table 110 : Sanofi: Company Snapshot
Table 111 : Sanofi: Financial Performance, FY 2022 and 2023
Table 112 : Sanofi: Product Portfolio
Table 113 : Sanofi: News/Key Developments, 2022-2024
Table 114 : Sekisui Diagnostics: Company Snapshot
Table 115 : Sekisui Diagnostics: Product Portfolio
Table 116 : Sekisui Diagnostics: News/Key Developments, 2024
Table 117 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 118 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
Table 119 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 120 : Thermo Fisher Scientific Inc.: News/Key Developments, 2021-2023
Table 121 : Viatris Inc.: Company Snapshot
Table 122 : Viatris Inc.: Financial Performance, FY 2022 and 2023
Table 123 : Viatris Inc.: Product Portfolio
Table 124 : List of Selected Emerging Startups

List of Figures

Summary Figure : Global Influenza Market Shares, by Region, 2023
Figure 1 : Porter's Five Forces Analysis of the Influenza Vaccines Market
Figure 2 : Supply Chain Analysis of Influenza Vaccine
Figure 3 : Market Dynamics of the Global Influenza Market
Figure 4 : Clinical Trial Studies of Influenza Vaccines, by Trial Phase, 2024
Figure 5 : Global Influenza Market Shares, by Product Segment, 2023
Figure 6 : Global Influenza Diagnostics Market Shares, by Type, 2023
Figure 7 : FDA-Approval of Influenza Detection Devices, 2015-January 2025
Figure 8 : Global Influenza Diagnostics Market Shares, by Region, 2023
Figure 9 : Global Influenza Vaccines Market Shares, by Type, 2023
Figure 10 : Global Influenza Vaccines Market Shares, by Region, 2023
Figure 11 : Global Influenza Therapeutics Market Shares, by Region, 2023
Figure 12 : Global Influenza Market Shares, by Region, 2023
Figure 13 : North American Influenza Market Shares, by Product Segment, 2023
Figure 14 : North American Influenza Market Shares, by Country, 2023
Figure 15 : Total Vaccine Doses Distributed in U.S., 2008-2023
Figure 16 : Influenza-Positive Tests Reported to the CDC by U.S. Clinical Laboratories, 2024-2025 Season
Figure 17 : The U.S. Influenza Market Shares, by Product Segment, 2023
Figure 18 : Influenza Detection in Canada, by Age Group and Report Week, 2024-2025 Season
Figure 19 : Canadian Influenza Market Shares, by Product Segment, 2023
Figure 20 : Mexican Influenza Market Shares, by Product Segment, 2023
Figure 21 : European Influenza Market Shares, by Product Segment, 2023
Figure 22 : European Influenza Market Shares, by Country, 2023
Figure 23 : German Influenza Market Shares, by Product Segment, 2023
Figure 24 : U.K. Influenza Market Shares, by Product Segment, 2023
Figure 25 : French Influenza Market Shares, by Product Segment, 2023
Figure 26 : Spanish Influenza Market Shares, by Product Segment, 2023
Figure 27 : Italian Influenza Market Shares, by Product Segment, 2023
Figure 28 : Rest of European Influenza Market Shares, by Product Segment, 2023
Figure 29 : Asia-Pacific Influenza Market Shares, by Product Segment, 2023
Figure 30 : Asia-Pacific Influenza Market Shares, by Country, 2023
Figure 31 : Chinese Influenza Market Shares, by Product Segment, 2023
Figure 32 : Japanese Influenza Market Shares, by Product Segment, 2023
Figure 33 : Indian Influenza Market Shares, by Product Segment, 2023
Figure 34 : Australian Influenza Market Shares, by Product Segment, 2023
Figure 35 : Rest of Asia-Pacific Influenza Market Shares, by Product Segment, 2023
Figure 36 : Rest of World Influenza Market Shares, by Product Segment, 2023
Figure 37 : Rest of World Influenza Market Shares, by Country, 2023
Figure 38 : South American Influenza Market Shares, by Product Segment, 2023
Figure 39 : Middle Eastern and African Influenza Market Shares, by Product Segment, 2023
Figure 40 : Company Share Analysis of Influenza Vaccine Market, 2023
Figure 41 : Company Share Analysis of Influenza Diagnostics Market, 2023
Figure 42 : Company Share Analysis of Influenza Therapeutics Market, 2023
Figure 43 : Abbott: Revenue Shares, by Business Unit, FY 2023
Figure 44 : Abbott: Revenue Shares, by Country/Region, FY 2023
Figure 45 : AstraZeneca: Revenue Shares, by Business Unit, FY 2023
Figure 46 : AstraZeneca: Revenue Shares, by Region/Country, FY 2023
Figure 47 : BD: Revenue Shares, by Business Unit, FY 2023
Figure 48 : BD: Revenue Shares, by Country/Region, FY 2023
Figure 49 : BioCryst Pharmaceuticals Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 50 : BioCryst Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 51 : CSL: Revenue Shares, by Business Unit, FY 2023
Figure 52 : CSL: Revenue Shares, by Country/Region, FY 2023
Figure 53 : Daiichi Sankyo Co. Ltd.: Revenue Shares, by Business Unit, FY 2023
Figure 54 : Daiichi Sankyo Co. Ltd.: Revenue Shares, by Country/Region, FY 2023
Figure 55 : Danaher Corp.: Revenue Shares, by Business Unit, FY 2023
Figure 56 : Danaher Corp.: Revenue Shares, by Region/Country, FY 2023
Figure 57 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2023
Figure 58 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2023
Figure 59 : GSK Plc.: Revenue Shares, by Business Unit, FY 2023
Figure 60 : GSK Plc.: Revenue Shares, by Country/Region, FY 2023
Figure 61 : Hologic Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 62 : Hologic Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 63 : QuidelOrtho Corp.: Revenue Shares, by Business Unit, FY 2023
Figure 64 : QuidelOrtho Corp.: Revenue Shares, by Country/Region, FY 2023
Figure 65 : Sanofi: Revenue Shares, by Business Unit, FY 2023
Figure 66 : Sanofi: Revenue Shares, by Country/Region, FY 2023
Figure 67 : Thermo Fisher Scientific Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 68 : Thermo Fisher Scientific Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 69 : Viatris Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 70 : Viatris Inc.: Revenue Shares, by Country/Region, FY 2023

Product Code: PHM049F

The global influenza market is expected to grow from $9.0 billion in 2024 and is projected to reach $12.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.2% during the forecast period of 2024 to 2029.

The North American influenza market is expected to grow from $4.5 billion in 2024 and is projected to reach $6.3 billion by the end of 2029, at a CAGR of 7.3% during the forecast period of 2024 to 2029.

The European influenza market is expected to grow from $2.4 billion in 2024 and is projected to reach $3.3 billion by the end of 2029, at a CAGR of 6.8% during the forecast period of 2024 to 2029.

Report Scope

This report presents qualitative and quantitative data on the current dynamics impacting the global influenza market. It examines the history of various flu pandemics, disease burden and vaccine coverage in several countries. The report thoroughly evaluates the market for influenza vaccines, therapeutics and diagnostics.

Analyses of the most popular products, clinical trials, new product approvals and emerging technologies are also included in the report. The demographics of the major regions-North America, Europe and Asia-Pacific-and their growth prospects are summarized. The profiles of leading companies and the strategies of international businesses involved in the influenza sector are also discussed.

The market size for influenza is categorized into three product segments: vaccines, therapeutics and diagnostics. Vaccines are further segmented into inactivated vaccines and live-attenuated vaccines. Diagnostics are divided into rapid and conventional lab tests. Additional growth potential and forecast data are addressed for the influenza market in each product segment for every region.

For market estimates, data are provided for 2023 as the base year, 2024 as the estimated year and forecast from 2025 through 2029.

Report Includes

55 data tables and 70 additional tables
An updated overview and in-depth analysis of the global influenza market
Analyses of the global market trends, with sales data from 2021-2024, and projections of compound annual growth rates (CAGRs) through 2029
Estimates of the actual market size and revenue forecasts, and a corresponding market share analysis by product segment, and region
Discussion of the role of major vaccine providers and companion products approved for a wide variety of influenza testing platforms, including adenovirus, SARS, parainfluenza, coronavirus and human metapneumovirus (hMPV)
Analysis of the market opportunities through the Porter's Five Forces model and PESTLE analysis, taking into consideration the prevailing micro- and macro environmental factors
Insight into the influenza industry structure, government regulations, and key development issues
Analysis of the key patent grants and IP aspects
A discussion of the industry's ESG challenges and practices of the industry
Analysis of the competitive landscape, featuring the leading participants, their current market rankings, and their market shares
Profiles of the leading companies, including Danaher Corp., Sanofi, CSL, La Roche Ltd., and Abbott

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview

Overview
Pandemic Scenario
Porter's Five Forces Analysis in the Influenza Vaccines Market
Potential of New Entrants (Moderate)
Bargaining Power of Suppliers (Moderate)
Bargaining Power of Buyers (Moderate to High)
Threat of Substitute Products or Services (Moderate)
Industry Rivalry (High)
Supply Chain Analysis
Vaccine Development
Vaccine Manufacturing
Storage and Inventory Management
Distribution
Administration and Immunization
Macroeconomic Factors Analysis
Impact of U.S.-China Trade War
Global Economic Growth
Demographic Trends
Public Health Crises and Pandemics

Chapter 3 Market Dynamics

Market Dynamics
Key Takeaways
Market Drivers
Development of Rapid Tests and Molecular Technologies
Government Support and Funding for Novel Therapies and Diagnosis
Rising Public Awareness About Flu Vaccines
Market Restraints
Therapeutic Market Dominated by Limited Suppliers
High Cost Associated with Storage and Supply of Flu Vaccines
Market Opportunities
Robust Pipeline of Influenza Vaccines
Demand for Improved Prevention, Treatment and Vaccine Accessibility

Chapter 4 Regulatory Landscape

Overview
Regulatory Aspects of Influenza Vaccines
Use of Trivalent Influenza Vaccines for the 2024-2025 U.S. Influenza Season
Influenza Vaccines Approved by EMA
Regulatory Scenario of Influenza Drugs
Approval Process of Influenza Detection Kit
Sensitivity
Specificity

Chapter 5 Emerging Trends and Pipeline Analysis

Overview
Advance in Influenza Diagnosis
SHINE Technology
Electrochemical Biosensors
Wearable Lab-on-a-Chip Devices
Quantum Dots and Fluorescent Nanoparticles
Role of AI in Influenza Diagnosis
Emerging Technologies in Influenza Vaccines
Universal Influenza Vaccine
mRNA-based Influenza Vaccines
Nanotechnology-based Vaccines
Patch-based Vaccines
Advances in Influenza Therapeutics
Nanoparticle-based Therapies
Potential Drug Agents in Clinical Trials
Patent Analysis
Key Takeaways

Chapter 6 Market Segmentation Analysis

Segmentation Breakdown
Global Influenza Market by Product Segment
Influenza Diagnostics
Influenza Vaccines
Influenza Therapeutics
Geographic Breakdown
Key Takeaways
North America
Europe
Asia-Pacific
Rest of World

Chapter 7 Competitive Intelligence

Company Share Analysis of the Influenza Vaccines Market
Company Share Analysis of Influenza Diagnostics Market
Company Share Analysis of Influenza Therapeutics Market
Venture Fundings and Investments Landscape
Key Developments in Market

Chapter 8 Sustainability in Influenza Market: ESG Perspective

Overview
ESG Risk Ratings
Conclusion

Chapter 9 Appendix

Methodology
Sources
Abbreviations
Company Profiles
ABBOTT
ASTRAZENECA
BD
BIOCRYST PHARMACEUTICALS INC.
CSL
DAIICHI SANKYO CO. LTD.
DANAHER CORP.
F. HOFFMANN-LA ROCHE LTD.
GSK PLC.
HOLOGIC INC.
QUIDELORTHO CORP.
SANOFI
SEKISUI DIAGNOSTICS
THERMO FISHER SCIENTIFIC INC.
VIATRIS INC.
Emerging Start-ups/Market Disruptors

インフルエンザの世界市場

The Global Influenza Market

目次

第1章エグゼクティブサマリー

第2章市場概要

第3章市場力学

第4章規制状況

第5章新たな動向とパイプライン分析

第6章市場セグメンテーション分析

第7章競合情報

第8章インフルエンザ市場における持続可能性：ESGの観点

第9章付録

List of Tables

List of Figures

Report Scope

Report Includes

Table of Contents

Chapter 1 Executive Summary

Chapter 2 Market Overview

Chapter 3 Market Dynamics

Chapter 4 Regulatory Landscape

Chapter 5 Emerging Trends and Pipeline Analysis

Chapter 6 Market Segmentation Analysis

Chapter 7 Competitive Intelligence

Chapter 8 Sustainability in Influenza Market: ESG Perspective

Chapter 9 Appendix

インフルエンザの世界市場

The Global Influenza Market

目次

第1章 エグゼクティブサマリー

第2章 市場概要

第3章 市場力学

第4章 規制状況

第5章 新たな動向とパイプライン分析

第6章 市場セグメンテーション分析

第7章 競合情報

第8章 インフルエンザ市場における持続可能性：ESGの観点

第9章 付録

List of Tables

List of Figures

Report Scope

Report Includes

Table of Contents

Chapter 1 Executive Summary

Chapter 2 Market Overview

Chapter 3 Market Dynamics

Chapter 4 Regulatory Landscape

Chapter 5 Emerging Trends and Pipeline Analysis

Chapter 6 Market Segmentation Analysis

Chapter 7 Competitive Intelligence

Chapter 8 Sustainability in Influenza Market: ESG Perspective

Chapter 9 Appendix

第1章エグゼクティブサマリー

第2章市場概要

第3章市場力学

第4章規制状況

第5章新たな動向とパイプライン分析

第6章市場セグメンテーション分析

第7章競合情報

第8章インフルエンザ市場における持続可能性：ESGの観点

第9章付録